Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

35 projects found matching your search criteria :

  1. Study of casein kinase CK2 inhibition mechanisms

    Call: OPUS 1 , Panel: ST5

    Principal investigator: prof. Maria Bretner

    Politechnika Warszawska, Wydział Chemiczny, Wydział Chemiczny

  2. The study of synergistic inhibition of tumor cell proliferation by CK2 casein kinase inhibitors and inhibitors of thymid...

    Call: OPUS 7 , Panel: NZ7

    Principal investigator: prof. Maria Bretner

    Politechnika Warszawska, Wydział Chemiczny

  3. Understanding the mechanism of action for small molecule kinase inhibitors in alleviating myotonic dystrophy type 1 (DM1...

    Call: OPUS 7 , Panel: NZ5

    Principal investigator: dr hab. Marzena Wojciechowska

    Instytut Chemii Bioorganicznej PAN

  4. Studies on the influence of selected inhibitors of kinases involved in signaling pathways in tumor cells on NK cell cyto...

    Call: PRELUDIUM 7 , Panel: NZ6

    Principal investigator: Marta Siernicka

    Warszawski Uniwersytet Medyczny, I Wydział Lekarski

  5. Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

    Call: OPUS 6 , Panel: NZ7

    Principal investigator: dr hab. Sylwia Flis

    Narodowy Instytut Leków

  6. Inhibitors of ER stress dependant PERK kinase as a novel approach for Alzheimer's therapy

    Call: HARMONIA 5 , Panel: NZ1

    Principal investigator: prof. Ireneusz Majsterek

    Uniwersytet Medyczny w Łodzi, Wydział Wojskowo-Lekarski

  7. Mechanism regulating vitamin D analog cooperation with cytostatics and tyrosine kinase inhibitors in non-small cell lung...

    Call: PRELUDIUM 5 , Panel: NZ4

    Principal investigator: dr Ewa Maj

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN

  8. Kinases of emerging relevance in cancer - structural characterization.

    Call: SONATA BIS 2 , Panel: NZ1

    Principal investigator: dr Grzegorz Dubin

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  9. Selective inhibition of Janus kinases for the treatment of autoimmune hepatitis: Translational PK/PD modelling from mole...

    Call: SONATA 19 , Panel: NZ7

    Principal investigator: dr Artur Świerczek

    Uniwersytet Jagielloński, Collegium Medicum

  10. Investigating the mechanisms of CD20 downregulation triggered by tyrosine kinase inhibitors in Philadelphia chromosome-p...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Krzysztof Domka

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

  11. Search for novel IKK-β inhibitors in the context of diseases with neuroinflammatory origin – structure-based drug design...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Emilia Sługocka

    Uniwersytet Jagielloński, Collegium Medicum

  12. Targeting Energy Metabolism for Precision Cancer Therapy: Novel Inhibitors of LDH-A and PDK1 as Potential Strategies to ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Marika Frańczak

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  13. Effects of tyrosine kinase inhibitors on Syk pathway in eNOS-based platelet subpopulations and on endothelial barrier in...

    Call: POLONEZ BIS 3 , Panel: NZ7

    Principal investigator: dr hab. Aneta Radziwon-Balicka

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  14. Small-molecule inhibitors of protein aggregation and ER stress as a novel strategy against neurodegeneration in the cour...

    Call: PRELUDIUM BIS 3 , Panel: NZ5

    Principal investigator: prof. Ireneusz Majsterek

    Uniwersytet Medyczny w Łodzi

  15. New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Anna Florczak

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  16. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Mikołaj Czajkowski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  17. Iron chelators as tyrosine kinase inhibitors - a new strategy for the treatment of glioblastoma multiforme

    Call: PRELUDIUM BIS 2 , Panel: NZ5

    Principal investigator: dr hab. Anna Mrozek-Wilczkiewicz

    Uniwersytet Śląski w Katowicach, Wydział Nauk Ścisłych i Technicznych

  18. Cell-based high-throughput screening for small-molecule compounds diminishing molecular markers of pathogenesis in myoto...

    Call: OPUS 20 , Panel: NZ3

    Principal investigator: dr hab. Marzena Wojciechowska

    Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

  19. A novel approach based on the optimized multidrug combination for glioblastoma treatment.

    Call: SONATA 16 , Panel: NZ7

    Principal investigator: dr Małgorzata Kucińska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  20. Molecular mechanisms of interplay between RORγ/RORγT receptors and cyclin-dependent kinase inhibitor (AT7519). Analysis ...

    Call: PRELUDIUM 18 , Panel: NZ7

    Principal investigator: Kaja Karaś

    Instytut Biologii Medycznej Polskiej Akademii Nauk

  21. Restoration of beta-cell function via inhibition of diabetic kinome.

    Call: SONATA BIS 9 , Panel: NZ1

    Principal investigator: dr Anna Czarna

    Uniwersytet Jagielloński

  22. The use of olaparib and ATR / CHK1 kinase inhibitors as a targeted anti-cancer therapy based on synthetic lethality

    Call: SONATA BIS 9 , Panel: NZ7

    Principal investigator: dr hab. Aneta Rogalska

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  23. Multitarget approach to break the vicious circle of tau pathology and neuroinflammation in Alzheimer's disease: developm...

    Call: SONATA BIS 9 , Panel: NZ7

    Principal investigator: dr hab. Anna Więckowska

    Uniwersytet Jagielloński, Collegium Medicum

  24. Comparative evaluation of effects of tyrosine kinase inhibitors (TKIs) on endothelial function in vivo in mice

    Call: PRELUDIUM 17 , Panel: NZ5

    Principal investigator: Brygida Marczyk

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  25. The significance of cancer specific PFK-II (PFKFB3 and PFKFB4) isoenzymes inhibition in overcoming resistance to BRAF in...

    Call: PRELUDIUM 16 , Panel: NZ5

    Principal investigator: Sonia Trojan

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Lekarski

  26. Deciphering molecular mechanism of CDK8 kinase inhibitors action in acute myeloid leukemia

    Call: SONATA BIS 8 , Panel: NZ2

    Principal investigator: dr hab. Michał Mikula

    Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

  27. Design of new small molecular regulators (inhibitors, activators) of the catalytic activity of adenylate kinases. Molecu...

    Call: OPUS 13 , Panel: ST4

    Principal investigator: dr Anna Kozakiewicz-Piekarz

    Uniwersytet Mikołaja Kopernika w Toruniu, Wydział Chemii

  28. Insights into biological activity and mechanism of action of novel styrylquinazoline derivatives as tyrosine kinase inhi...

    Call: PRELUDIUM 12 , Panel: NZ7

    Principal investigator: Katarzyna Malarz

    Uniwersytet Śląski w Katowicach, Wydział Matematyki, Fizyki i Chemii

  29. Use of novel small molecule inhibitors of PERK kinase dependent UPR pathway for the colorectal cancer treatment

    Call: OPUS 12 , Panel: NZ5

    Principal investigator: prof. Adam Dziki

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  30. Analysis of the effectiveness of anticancer activity of tyrosine kinase inhibitors combined with nanoparticles in in vit...

    Call: SONATA 11 , Panel: ST4

    Principal investigator: dr Natalia Piergies

    Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego Polskiej Akademii Nauk

  31. Use of novel small molecule inhibitors of PERK kinase dependent UPR pathway for the primary open-angle glaucoma treatmen...

    Call: OPUS 11 , Panel: NZ5

    Principal investigator: prof. Ireneusz Majsterek

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  32. New opportunities for use of PERK kinase inhibitors in eIF2alfa factor-dependant signalling pathway in antitumor therapy

    Call: PRELUDIUM 10 , Panel: NZ3

    Principal investigator: dr Wioletta Rozpędek-Kamińska

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  33. Synthesis of new glutamate receptors antagonists and extensive investigation of their effect on tumor cells in the prese...

    Call: OPUS 9 , Panel: ST5

    Principal investigator: prof. Maria Bretner

    Politechnika Warszawska, Wydział Chemiczny

  34. New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

    Call: OPUS 9 , Panel: ST5

    Principal investigator: prof. Artur Terzyk

    Uniwersytet Mikołaja Kopernika, Wydział Chemii

  35. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

    Call: PRELUDIUM 9 , Panel: NZ5

    Principal investigator: Zofia Bielecka

    Wojskowy Instytut Medyczny

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy